Improving the retention rate for residential treatment of substance abuse by sequential intervention for social anxiety

BMC Psychiatry

Stefan Gruenert³  Alexandra Howard¹  Nicolas Kambouropoulos¹  James S Williams¹  Michael Kyrios²  Petra K Staiger¹ 

[1] Deakin University, School of Psychology, Faculty of Health, Medicine, Nursing and Behavioural Sciences, Burwood, Australia;Swinburne University, Brain and Psychological Sciences Research Centre, Hawthorn, Australia;Odyssey House, Victoria, Richmond, Australia

关键词: Randomised control trial;    Therapeutic community;    Residential drug treatment;    Treatment retention;    Social anxiety;    Substance dependence;   

Others  :  1123774
DOI  :  10.1186/1471-244X-14-43

 received in 2013-10-29, accepted in 2014-02-12,  发布年份 2014

【 摘 要 】

Background

Residential drug rehabilitation is often seen as a treatment of last resort for people with severe substance abuse issues. These clients present with more severe symptoms, and frequent psychiatric comorbidities relative to outpatients. Given the complex nature of this client group, a high proportion of clients seeking treatment often do not enter treatment, and of those who do, many exit prematurely. Given the highly social nature of residential drug rehabilitation services, it has been argued that social anxieties might decrease the likelihood of an individual entering treatment, or increase the likelihood of them prematurely exiting treatment. The current paper reports on the protocol of a Randomised Control Trial which examined whether treatment of social anxiety prior to entry to treatment improves entry rates and retention in residential drug rehabilitation.

Method/design

A Randomised Control Trial comparing a social skills treatment with a treatment as usual control group was employed. The social skills training program was based on the principles of Cognitive Behaviour Therapy, and was adapted from Ron Rapee’s social skills training program. A permutated block randomisation procedure was utilised. Participants are followed up at the completion of the program (or baseline plus six weeks for controls) and at three months following entry into residential rehabilitation (or six months post-baseline for participants who do not enter treatment).

Discussion

The current study could potentially have implications for addressing social anxiety within residential drug treatment services in order to improve entry and retention in treatment. The results might suggest that the use of additional screening tools in intake assessments, a focus on coping with social anxieties in support groups for clients waiting to enter treatment, and greater awareness of social anxiety issues is warranted.

Australian New Zealand clinical trials registry

Australian New Zealand Clinical Trials Registry (ACTRN) registration number: ACTRN12611000579998

【 授权许可】

   
2014 Staiger et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Vergara-Moragues E, González-Saiz F, Lozano OM, García AV: Psychiatric profile of three-month retention in cocaine- dependent patients treated in a therapeutic community. J Stud Alcohol Drugs 2013, 74(3):452-459.
• [2]Astals M, Díaz L, Domingo-Salvany A, Martín-Santos R, Bulbena A, Torrens M: Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study. Int J Environ Res Publ Health 2009, 6(11):2822-2832.
• [3]Fowler JC, Groat M, Ulanday M: Attachment style and treatment completion among psychiatric inpatients with substance use disorders. Am J Addict 2013, 22(1):14-17.
• [4]Stark MJ: Dropping out of substance abuse treatment: a clinically oriented review. Clin Psychol Rev 1992, 12(1):93-116.
• [5]Randall CL, Thomas S, Thevos AK: Concurrent alcoholism and social anxiety disorder: a first step toward developing effective treatments. Alcohol Clin Exp Res 2001, 25(2):210-220.
• [6]Etheridge RM, Hubbard RL, Anderson J, Craddock SG, Flynn PM: Treatment structure and program services in the drug abuse treatment outcome study (DATOS). Psychol Addict Behav 1997, 11(4):244-260.
• [7]De Leon G: Chapter 66 - therapeutic communities. In Interventions for Addiction. Edited by Peter MM. San Diego: Academic; 2013:643-653.
• [8]Budde D, Rounsaville B, Bryant K: Inpatient and outpatient cocaine abusers: clinical comparisons at intake and one-year follow-up. J Subst Abuse Treat 1992, 9(4):337-342.
• [9]Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, Cooke R: The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev 2005, 24(5):411-418.
• [10]Eland-Goossensen A, van de Goor IAM, Garretsen HFL: Heroin addicts in the community and in treatment compared for severity of problems and need for help. Subst Use Misuse 1997, 32(10):1313-1330.
• [11]Ross S, Dermatis H, Levounis P, Galanter M: A comparison between dually diagnosed inpatients with and without Axis II comorbidity and the relationship to treatment outcome. Am J Drug Alcohol Abuse 2003, 29(2):263-279.
• [12]Weinstock J, Alessi SM, Petry NM: Regardless of psychiatric severity the addition of contingency management to standard treatment improves retention and drug use outcomes. Drug Alcohol Depend 2007, 87(2–3):288-296.
• [13]Polimeni A-M, Moore S, Gruenert S: MMPI-2 profiles of clients with substance dependencies accessing a therapeutic community treatment facility Electronic. J Appl Psychol 2010, 6(1):1-9.
• [14]Australian Institute of Health and Welfare Canberra: Alcohol and other drug treatment services in Australia 2011–12. In Drug treatment series 21 Cat no HSE139. Canberra: AIHW; 2013.
• [15]Johns K, Baker A, Webster RA, Lewin TJ: Factors associated with retention in a long-term residential rehabilitation programme for women with substance use problems. Ment Health Subst Use Dual Diagn 2009, 2(1):40-51.
• [16]Mandell W, Edelen MO, Wenzel SL, Dahl J, Ebener P: Do dimensions of therapeutic community treatment predict retention and outcomes? J Subst Abuse Treat 2008, 35(3):223-231.
• [17]De Leon G: Is the therapeutic community an evidence-based treatment? What the evidence says. Ther Communities 2010, 31(2):104-128.
• [18]Vanderplasschen W, Colpaert K, Autrique M, Rapp RC, Pearce S, Broekaert E, Vandevelde S: Therapeutic communities for addictions: a review of their effectiveness from a recovery-oriented perspective. Sci World J 2013, 2013:427817.
• [19]Darke S, Ross J, Teesson M: The Australian treatment outcome study (ATOS): what have we learnt about treatment for heroin dependence? Drug Alcohol Rev 2007, 26(1):49-54.
• [20]Simpson DD, Joe GW, Broome KM, Hiller ML, Knight K, Rowan-Szal GA: Program diversity and treatment retention rates in the drug abuse treatment outcome study (DATOS). Psychol Addict Behav 1997, 11(4):279-293.
• [21]Simpson DD, Joe GW, Rowan-Szal GA: Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend 1997, 47(3):227-235.
• [22]Zhang Z, Friedmann PD, Gerstein DR: Does retention matter? Treatment duration and improvement in drug use. Addiction 2003, 98(5):673-684.
• [23]Condelli WS, De Leon G: Fixed and dynamic predictors of client retention in therapeutic communities. J Subst Abuse Treat 1993, 10(1):11-16.
• [24]Buckner JD, Heimberg RG, Ecker AH, Vinci C: A biopsychosocial model of social anxiety and substance use. Depress Anxiety 2013, 30(3):276-284.
• [25]Teesson M, Havard A, Fairbairn S, Ross J, Lynskey M, Darke S: Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking. Drug Alcohol Depend 2005, 78(3):309-315.
• [26]Brunello N, den Boer JA, Judd LL, Kasper S, Kelsey JE, Lader M, Lecrubier Y, Lepine JP, Lydiard RB, Mendlewicz J, et al.: Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. J Affect Disord 2000, 60(1):61-74.
• [27]World Health Organization: The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
• [28]Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC: Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the national comorbidity survey. Arch Gen Psychiatr 1997, 54(4):313-321.
• [29]Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ: The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization. Am J Orthopsychiatry 1996, 66(1):17-31.
• [30]Teesson M, Hall W, Lynskey M, Degenhardt L: Alcohol- and drug-use disorders in Australia: implications of the national survey of mental health and wellbeing. Aust N Z J Psychiatr 2000, 34(2):206-213.
• [31]Bakken K, Landheim AS, Vaglum P: Substance-dependent patients with and without social anxiety disorder: occurrence and clinical differences: a study of a consecutive sample of alcohol-dependent and poly-substance-dependent patients treated in two counties in Norway. Drug Alcohol Depend 2005, 80(3):321-328.
• [32]Kushner MG, Sher KJ, Beitman BD: The relation between alcohol problems and the anxiety disorders. Am J Psychiatr 1990, 147(6):685-695.
• [33]Book SW, Randall CL: Social anxiety disorder and alcohol use. Alcohol Res Health 2002, 26(2):130-135.
• [34]Havard A, Teesson M, Darke S, Ross J: Depression among heroin users: 12-Month outcomes from the Australian treatment outcome study (ATOS). J Subst Abuse Treat 2006, 30(4):355-362.
• [35]Liappas J, Paparrigopoulos T, Tzavellas E, Christodoulou G: Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. J Affect Disord 2003, 76(1–3):279-284.
• [36]Litman GK, Eiser JR, Rawson NSB, Oppenheim AN: Differences in relapse precipitants and coping behaviour between alcohol relapsers and survivors. Behav Res Ther 1979, 17(2):89-94.
• [37]McNeil DW: Terminology and evolution of constructs in social anxiety and social phobia. In From social anxiety to social phobia: Multiple perspectives. Edited by Hofmann SG, DiBartolo PM, Needham H. MA US: Allyn & Bacon; 2001:8-19.
• [38]Stein MB, Torgrud LJ, Walker JR: Social phobia symptoms, subtypes, and severity: findings from a community survey. Arch Gen Psychiatr 2000, 57(11):1046-1052.
• [39]Vriends N, Becker ES, Meyer A, Michael T, Margraf J: Subtypes of social phobia: are they of any use? J Anxiety Disord 2007, 21(1):59-75.
• [40]Ruscio AM: The latent structure of social anxiety disorder: consequences of shifting to a dimensional diagnosis. J Abnorm Psychol 2010, 119(4):662-671.
• [41]Crome E, Baillie A, Slade T, Ruscio AM: Social phobia: further evidence of dimensional structure. Aust New Zealand J Psychiatr 2010, 44(11):1012-1020.
• [42]Kollman DM, Brown TA, Liverant GI, Hofmann SG: A taxometric investigation of the latent structure of social anxiety disorder in outpatients with anxiety and mood disorders. Depress Anxiety 2006, 23(4):190-199.
• [43]Crum RM, Pratt LA: Risk of heavy drinking and alcohol use disorders in social phobia: a prospective analysis. Am J Psychiatr 2001, 158(10):1693-1700.
• [44]Weeks JW, Carleton RN, Asmundson GJG, McCabe RE, Antony MM: "Social Anxiety Disorder Carved at its Joints": evidence for the taxonicity of social anxiety disorder. J Anxiety Disord 2010, 24(7):734-742.
• [45]El-Sayegh S, Fattal O, Muzina DJ: Is social anxiety disorder unrecognized in patients with substance dependence? Addict Dis Their Treat 2006, 5(3):145-151.
• [46]Terra MB, Barros HMT, Stein AT, Figueira I, Athayde LD, Spanemberg L, De Aguiar PM, Filho LD, Da Silveira DX: Does co-occurring social phobia interfere with alcoholism treatment adherence and relapse? J Subst Abuse Treat 2006, 31(4):403-409.
• [47]Wyman K, Castle DJ: Anxiety and substance use disorder comorbidity: prevalence, explanatory models and treatment implications. J Dual Diagn 2006, 2(4):93-119.
• [48]Schadé A, Marquenie LA, van Balkom AJLM, Koeter MWJ, de Beurs E, van den Brink W, van Dyck R: The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. Alcohol Clin Exp Res 2005, 29(5):794-800.
• [49]Baillie AJ, Sannibale C, Stapinski LA, Teesson M, Rapee RM, Haber PS: An investigator-blinded, randomized study to compare the efficacy of combined CBT for alcohol use disorders and social anxiety disorder versus CBT focused on alcohol alone in adults with comorbid disorders: The Combined Alcohol Social Phobia (CASP) trial protocol. BMC Psychiatr 2013, 13:199. BioMed Central Full Text
• [50]Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001, 357(9263):1191-1194.
• [51]Rapee RM: Overcoming shyness and social phobia: a step by step guide. : Jason Aronson, Inc; 1998.
• [52]Rapee RM, Abbott MJ, Baillie AJ, Gaston JE: Treatment of social phobia through pure self-help and therapist-augmented self-help. Br J Psychiatr 2007, 191(3):246-252.
• [53]Wilson JK, Rapee RM: The interpretation of negative social events in social phobia: changes during treatment and relationship to outcome. Behav Res Ther 2005, 43(3):373-389.
• [54]Liebowitz MR: Social phobia. Mod Probl Pharmacopsychiatr 1987, 22:141-173.
• [55]American Psychiatric Association: Diagnostic & statistical manual of mental disorders: DSM-IV-TR. 4th edition. Washington, D.C: American Psychiatric Association; 2000.
• [56]Merikangas KR, Avenevoli S, Acharyya S, Zhang H, Angst J: The spectrum of social phobia in the zurich cohort study of young adults. Biol Psychiatr 2002, 51(1):81-91.
• [57]Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatr 1998, 59(SUPPL. 20):22-33.
• [58]Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, Janavs J, Dunbar GC: The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatr 1997, 12(5):224-231.
• [59]W.H.O. Assist Working Group: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction 2002, 97(9):1183-1194.
• [60]Newcombe DAL, Humeniuk RE, Ali R: Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): report of results from the Australian site. Drug Alcohol Rev 2005, 24(3):217-226.
• [61]Sobell LC, Sobell MB: Timeline Follow-Back: A technique for assessing self-reported ethanol consumption. In Measuring Alcohol Consumption: Psychosocial and Biological Methods. Edited by Allen J, Litten RZ. NJ: Humana Press; 1992:41-72.
• [62]Douglas SM, Fresco DM, Heimberg RG, Schneier FR, Davies SO, Liebowitz MR: Screening for social anxiety disorder in the clinical setting: using the leibowitz social anxiety scale. Anxiety Disord 2002, 16:661-673.
• [63]Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, Liebowitz MR: Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 1999, 29(01):199-212.
• [64]Fresco DM, Coles ME, Heimberg RG, Liebowitz MR, Hami S, Stein MB, Goetz D: The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered formats. Psychol Med 2001, 31(06):1025-1035.
• [65]Beck AT, Epstein N, Brown G, Steer RA: An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988, 56(6):893-897.
• [66]Beck AT, Steer RA, Brown G: Manual for the Beck Depression Inventory-II. TX: Psychological Corporation; 1996.
• [67]Beck AT, Steer RA, Ball R, Ranieri WF: Comparison of beck depression inventories-IA and-II in psychiatric outpatients. J Pers Assess 1996, 67(3):588-597.
• [68]De Leon G, Melnick G, Kressel D, Jainchill N: Circumstances, motivation, readiness, and suitability (the CMRS scales): predicting retention in therapeutic community treatment. Am J Drug Alcohol Abuse 1994, 20(4):495-515.
• [69]Attkisson CC, Greenfield TK: Client Satisfaction Questionnaire-8 and Service Satisfaction Scale-30. In The use of psychological testing for treatment planning and outcome assessment. Hillsdale, NJ, England: Lawrence Erlbaum Associates, Inc; 1994:402-420.
• [70]Staiger P, Lake A, Long C: Preventing Relapse: A Responsible Drinking Program for Recovering Drug Users. Melbourne, Australia: Deakin University; 2011.
• [71]Simpson DD, Joe GW: A longitudinal evaluation of treatment engagement and recovery stages. J Subst Abuse Treat 2004, 27(2):89-97.